House and Senate Appropriators Pledge to Increase Biomedical Research Funding.
Schilskly Promoted to Associate Dean At Chicago, Vogelzang To Direct Center
Clinical Trials: NIH Health Plans Association, Agree In Principle to Raise Clinical Trial Enrollment
Cancer Screenings: American Over 50 Urged to Get Colon Caner Tests
Cancer Prevention: HHS Calls for Warning Labels on Cigars, Says Teen Use High
Funding Opportunities: NCI Offers Grant Supplements
Foon To Direct Barrett Center; Hundahl Leads Commission
National Comprehensive Center Network, Quintiles Oncology, To Collaborate On Trials
Oncology ManagementL Tax-Exempt Bonds Issued To Expand UPCI; Sentillion, Dua Partner on Info System
Clinical Trials: Phase I Trial of Karenitecin Begins, BioNumerik Says
Approvals and Applications: European Committee Signs Off On Paxene for KS reatment
Patents: Myriad Patents Spectrometry To Assess DNA Polymorphisms
Deals and Collaborations: Firms Get First Payment From Bristol-Myers for Taxol
Oncology ManagementL AOR earns $30 Million, PRN Earns $29.8 Million
Trending Stories
- As his Senate testimony alleged danger from mRNA COVID vaccine, El-Deiry had an offer to run NCI Frederick lab
The job offer to run the lab—home to virus research, RAS Initiative, and data science—was quickly rescinded - Pancreatic cancer breakthrough came from smart scientists making smart bets—not from politicization of science
- The story of daraxonrasib is the ultimate hero’s journey
A narrative curve with twists, turns, intrigue, drama—and a blow to a mighty foe - Proposed OMB rule aims at the heart of the U.S. research enterprise—and scientists are fighting back
“The question isn’t whether politics will influence research. Under this proposal, that’s the point. That’s their goal.” - At Senate hearing, Brown’s El-Deiry and other witnesses say they were targeted for arguing that mRNA vaccine may be linked to cancer
- Pancreatic cancer finally starts to budge as daraxonrasib doubles overall survival
